OptiNose Receives FDA Approval to Expand Xhance Labeling for Chronic Sinusitis Therapy

Saturday, 16 March 2024, 12:37

OptiNose stock surged as the FDA granted approval for expanding Xhance labeling to include treatment for chronic sinusitis in adults, with or without nasal polyps. This strategic move opens up new market opportunities and is expected to positively impact OptiNose's performance in the sinusitis therapy sector.

https://store.livarava.com/9796c0aa-e392-11ee-9675-5254a2021b2b.jpe — OptiNose Receives FDA Approval to Expand Xhance Labeling for Chronic Sinusitis Therapy

OptiNose Granted FDA Approval for Xhance Labeling Expansion

OptiNose (OPTN) stock gained after FDA approval to expand Xhance labeling to treat chronic sinusitis in adults with or without nasal polyps.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

OptiNose Granted FDA Approval for Xhance Labeling Expansion

Related posts